Pimea AI
A personalized healthcare app (mHealth) for allergies that accesses the subconscious mind to retrain the immune system to avoid, or reduce, allergy inflammation for a long period
Company Overview
Snapshot
Founded in June 2022 by Omer Hevlin, Pimea AI operates with 1–10 employees. The company is currently in the Pre-Funding stage and holds one patent, indicating early-stage development and intellectual property protection.
Business overview
Pimea AI is developing a digital personalized healthcare therapy to address the global allergy industry. The company's core technology utilizes advanced algorithms to analyze patients' physiological parameters and administer a proprietary therapeutic protocol. This protocol aims to access the subconscious mind to retrain the immune system, reducing allergy inflammation and preventing symptoms for extended periods. Rooted in psychoneuroimmunology and holistic healthcare, Pimea AI serves the global market, targeting both B2C and B2B2C segments within the Health Tech & Life Sciences sector, specifically focusing on Digital Therapeutics and Medical Treatment & Therapeutics.
Company Intelligence Q&A
- What is Pimea AI's primary focus?
- Pimea AI focuses on developing a personalized digital healthcare therapy for allergies, aiming to retrain the immune system to reduce or avoid allergy inflammation.
- When was Pimea AI founded?
- Pimea AI was founded in June 2022.
- Who is the founder of Pimea AI?
- Omer Hevlin is the Founder & CEO of Pimea AI.
- What is Pimea AI's current product development stage?
- Pimea AI's product, Pimea Allergy, is currently in the Research & Development (R&D) stage. The company holds one patent, indicating early-stage development and intellectual property protection for its digital personalized healthcare therapy.
- What business models does Pimea AI utilize?
- Pimea AI operates with B2C, B2B2C, and B2B business models.